Support guide for symptom assessment in patients with myeloproliferative syndromes using the mpn-10 scale

Authors

  • Andreia Rocha Centro Ambulatório, Hospitais de Dia, Hospital de Santa Maria
  • Cláudia Ricou Hospital de Dia de Oncologia, Hospital de São Francisco Xavier
  • Elisabete Pereira Centro Ambulatório, Hospitais de Dia, Hospital de Santa Maria
  • Elisabete Valério Clínica da Mama, IPO Porto
  • Júan Sanchez Hospital de Dia de Oncologia, Hospital de São Francisco Xavier
  • M. Jorge Freitas Departamento Radioterapia, IPO Porto, Porto
  • Márcia Caeiro Hematologia Clínica, Hospital Santo António Capuchos, Lisboa
  • Maria Sarmento Unidade de Hematologia Clínica, ULS de Matosinhos
  • Marta Duarte Unidade de Hematologia Clínica, ULS de Matosinhos
  • Sandra Ponte Hospital de Dia Oncologia, Hospital de S. Francisco Xavier
  • Sónia Frias Centro Ambulatório, Hospitais de Dia, Hospital de Santa Maria

Keywords:

Myeloproliferative neoplasms, Symptoms, MPN-10

Abstract

Myeloproliferative neoplasms (PH-) – Myelofibrosis, Polycythemia Vera and Essential Thrombocythemia – represents a heterogeneous disorders of the hematopoietic system associated with debilitating symptoms with consequent reduction of the quality of life and negative impact on the daily activities of of patients. The National Comprehensive Cancer Network (NCCN) guidelines, based on the Myeloproliferative Neoplasm Symptom Assessment Form, Total Symptom Score (MPN-SAF TSS) tool, were initiated by some Portuguese hospitals and began monitoring and, systematically, evaluating the symptoms of these patients. This tool, validated for the Portuguese language, has been applied with the support of the nursing teams. In Nurses Focus Group model they discuss the main challenges in using the MPN-10 assessment tool, following which the present guide was developed. The most relevant aspects of the application of this tool were identified: 1) to take into account that it is a self-completion scale; 2) the tool aims to assess the impact of the symptom using numerical categories and 3) the healthcare professionals should not refer / induce the patient for comparison with previous evaluations. To facilitate the understanding of the MPN-10 and methodology of filling by the patient, additional information was developed on each of the symptoms for use by the health professional at the moment of information/clarification to the patient.

Downloads

Download data is not yet available.

References

Almeida A, Macedo A, Afonso C, Trindade MC, Pinho Vaz C, Montalvão A, Polo B, Araújo LF, Costa C, Guerra L. (Nov 2016). Tradução e validação linguística da ferramenta PMN10 para graduação de sintomas em doentes com Neoplasias Mieloproliferativas em Portugal. Poster presented at the SPH National Meeting. Aveiro, Portugal.

Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, Pollyea DA, Rampal R, Rein LA, Scott B, Snyder DS, Stein BL, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Dec;14(12):1572-1611. PubMed PMID: 27956542.

Harrison, C.N et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematolo 2017 96.1653-1995

Arber DA et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127(20):2391-405

Emanuel RM, et al. Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. J Clin Oncol. 2012; 30 (33): 4098-4103.

FDA. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, Dec 2009; EMA. Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man, 2014; EMA/CHMP/292464/2014

Published

2018-06-20

How to Cite

1.
Rocha A, Ricou C, Pereira E, Valério E, Sanchez J, Jorge Freitas M, Caeiro M, Sarmento M, Duarte M, Ponte S, Frias S. Support guide for symptom assessment in patients with myeloproliferative syndromes using the mpn-10 scale. Onco.News [Internet]. 2018 Jun. 20 [cited 2024 Nov. 29];(36):41-4. Available from: https://onco.news/index.php/journal/article/view/77